FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588538618> ?p ?o ?g. }

• W2588538618 abstract "Abstract Abstract 2952 Introduction: Carfilzomib (Onyx Pharmaceuticals, South San Francisco, CA, USA) is an irreversible proteasome inhibitor (PI) that has shown preclinical and clinical efficacy against multiple myeloma (MM). It has shown clinical benefit as a single agent and with steroids in early clinical trials, even among patients resistant to prior bortezomib treatment. We determined the anti-MM effects of carfilzomib in combination with cyclophosphamide (CY) or bendamustine (Ben) in vivo using our xenograft model of human MM, LAGk-1A. Methods: Each SCID mouse received a 20 – 40 mm3 MM tumor piece surgically implanted into the hind limb. Seven days post-implantation mice were bled, human IgG levels were measured by ELISA and mice randomized into groups. Carfilzomib stock solution (2 mg/ml) was diluted to 3 mg/kg using 10% capsitol and administered twice weekly via intravenous (i.v.) injection. Cyclophosphamide (Baxter, Deerfield, IL, USA) stock solution (20 mg/ml) was diluted in sodium chloride and administered via oral gavage once weekly at 10 mg/kg. Bendamustine (Teva Pharmaceuticals, North Wales, PA, USA) stock solution (5 mg/ml) was diluted to 5 mg/kg in sterile water and administered via intraperitoneal (i.p.) once weekly. Mice (n = 8) were bled to determine hIgG levels and the tumors were measured using standard calipers. Data was analyzed as the mean ± SEM. Results: LAGk-1A-bearing mice treated with single agent carfilzomib or CY did not show a reduction in tumor growth compared to vehicle-treated mice. In contrast, the combination of carfilzomib plus CY resulted in a statistically significant decrease in tumor size and IgG levels when compared to vehicle-treated mice on days 35, 42, 49, and 56 (tumor volume; P = 0.0007, P = 0.0003, P = 0.0008 and P = 0.0001: IgG levels; P = 0.0023, P = 0.0327, P = 0.0219 and P = 0.0190, respectively). Toxicity was minimal as seven of eight mice survived this combination regimen. Furthermore, tumor growth delay (TGD) to a volume of 1,125 mm3 was delayed by 53.6% (22 days, day 41 for control compared to day 63 for the carfilzomib + CY group) among animals receiving this combination treatment regimen when compared to vehicle-treated animals. In contrast, shorter TGDs were obtained when mice were dosed with single agents. When mice were dosed with carfilzomib alone, a TGD of 12.1% (5 days, day 41 for control compared to day 46 for the carfilzomib group) was obtained. When mice were dosed with CY alone, a TGD of 26.8% (11 days, day 41 for control compared to day 52 for the CY group) was obtained. Percentage inhibition of tumor growth (T/C) is represented as the median tumor volume of the test drug group over the median tumor volume of the vehicle group. A T/C ratio of ≤42% is indicative of drug efficacy. At day 56 post tumor implantation, mice receiving single agent treatment with carfilzomib or CY had T/C's of 88% and 67%, respectively. In contrast, at the same time point, mice receiving the cafilzomib plus CY regimen resulted in a lower percentage T/C of 29%. We also evaluated the combination of carfilzomib plus Ben in LAGk-1A-bearing mice. Animals treated with single agents did not result in a reduction in tumor volume compared to vehicle-treated mice. In contrast, the combination of carflzomib and Ben resulted in a decrease in tumor size compared to vehicle-treated mice on days 35, 42, 49, and 56 (P = 0.0184, P < 0.0001, P = 0.0035, and P = 0.0026, respectively). Additionally, this combination resulted in a reduction in IgG levels compared to vehicle-treated mice on days 42, 49 and 56 (P = 0.0426, P = 0.0257 and P = 0.0204, respectively). Furthermore, six of eight mice survived this treatment regimen. Compared to vehicle-treated mice, animals treated with the combination treatment showed a TGD to 1,250 mm3 of 38% (16 days, day 42 for control compared to day 58 for the carfilzomib + Ben). When compared to vehicle-treated mice, carfilzomib-treated animals showed a TGD of only 14.3% (6 days, day 42 for control compared to day 48 for the carfilzomib), and there was no TGD for mice treated with Ben alone. Conclusions: We have shown that the combination of carfilzomib plus CY or Ben shows marked anti-MM effects using our xenograft MM model LAGk-1A. The results from these preclinical studies provide the basis for clinical trials evaluating the combination of carfilzomib with CY or Ben for patients with MM. Disclosures: Berenson: Onyx: Consultancy, Honoraria, Speakers Bureau." @default.
• W2588538618 created "2017-02-24" @default.
• W2588538618 creator A5038431825 @default.
• W2588538618 creator A5040835019 @default.
• W2588538618 creator A5061288330 @default.
• W2588538618 creator A5085360438 @default.
• W2588538618 creator A5090300095 @default.
• W2588538618 date "2012-11-16" @default.
• W2588538618 modified "2023-09-27" @default.
• W2588538618 title "Anti-Myeloma Effects of Carfilzomib with Cyclophosphamide (CY) or Bendamustine (Ben)." @default.
• W2588538618 doi "https://doi.org/10.1182/blood.v120.21.2952.2952" @default.
• W2588538618 hasPublicationYear "2012" @default.
• W2588538618 type Work @default.
• W2588538618 sameAs 2588538618 @default.
• W2588538618 citedByCount "0" @default.
• W2588538618 crossrefType "journal-article" @default.
• W2588538618 hasAuthorship W2588538618A5038431825 @default.
• W2588538618 hasAuthorship W2588538618A5040835019 @default.
• W2588538618 hasAuthorship W2588538618A5061288330 @default.
• W2588538618 hasAuthorship W2588538618A5085360438 @default.
• W2588538618 hasAuthorship W2588538618A5090300095 @default.
• W2588538618 hasConcept C126322002 @default.
• W2588538618 hasConcept C126894567 @default.
• W2588538618 hasConcept C2776364478 @default.
• W2588538618 hasConcept C2776694085 @default.
• W2588538618 hasConcept C2776755627 @default.
• W2588538618 hasConcept C2777478702 @default.
• W2588538618 hasConcept C2779338263 @default.
• W2588538618 hasConcept C2780108899 @default.
• W2588538618 hasConcept C2780653079 @default.
• W2588538618 hasConcept C2781442060 @default.
• W2588538618 hasConcept C71924100 @default.
• W2588538618 hasConcept C98274493 @default.
• W2588538618 hasConceptScore W2588538618C126322002 @default.
• W2588538618 hasConceptScore W2588538618C126894567 @default.
• W2588538618 hasConceptScore W2588538618C2776364478 @default.
• W2588538618 hasConceptScore W2588538618C2776694085 @default.
• W2588538618 hasConceptScore W2588538618C2776755627 @default.
• W2588538618 hasConceptScore W2588538618C2777478702 @default.
• W2588538618 hasConceptScore W2588538618C2779338263 @default.
• W2588538618 hasConceptScore W2588538618C2780108899 @default.
• W2588538618 hasConceptScore W2588538618C2780653079 @default.
• W2588538618 hasConceptScore W2588538618C2781442060 @default.
• W2588538618 hasConceptScore W2588538618C71924100 @default.
• W2588538618 hasConceptScore W2588538618C98274493 @default.
• W2588538618 hasLocation W25885386181 @default.
• W2588538618 hasOpenAccess W2588538618 @default.
• W2588538618 hasPrimaryLocation W25885386181 @default.
• W2588538618 hasRelatedWork W120369407 @default.
• W2588538618 hasRelatedWork W131998332 @default.
• W2588538618 hasRelatedWork W1443108546 @default.
• W2588538618 hasRelatedWork W1483779827 @default.
• W2588538618 hasRelatedWork W2320930530 @default.
• W2588538618 hasRelatedWork W2328602479 @default.
• W2588538618 hasRelatedWork W2349623012 @default.
• W2588538618 hasRelatedWork W2361444327 @default.
• W2588538618 hasRelatedWork W2376365909 @default.
• W2588538618 hasRelatedWork W2380703843 @default.
• W2588538618 hasRelatedWork W2380807696 @default.
• W2588538618 hasRelatedWork W2388762021 @default.
• W2588538618 hasRelatedWork W2404733004 @default.
• W2588538618 hasRelatedWork W2557733183 @default.
• W2588538618 hasRelatedWork W2558296050 @default.
• W2588538618 hasRelatedWork W2572796572 @default.
• W2588538618 hasRelatedWork W2582838532 @default.
• W2588538618 hasRelatedWork W2588974447 @default.
• W2588538618 hasRelatedWork W2978553166 @default.
• W2588538618 hasRelatedWork W3030508989 @default.
• W2588538618 isParatext "false" @default.
• W2588538618 isRetracted "false" @default.
• W2588538618 magId "2588538618" @default.
• W2588538618 workType "article" @default.